for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novacyt SA

NCYT.L

Latest Trade

99.00GBp

Change

21.50(+27.74%)

Volume

8,377,748

Today's Range

78.90

 - 

99.00

52 Week Range

6.03

 - 

108.90

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
77.50
Open
84.50
Volume
8,377,748
3M AVG Volume
144.12
Today's High
99.00
Today's Low
78.90
52 Week High
108.90
52 Week Low
6.03
Shares Out (MIL)
37.66
Market Cap (MIL)
72.81
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Novacyt Receives Notice Of Exercise Of Warrants For New Shares

Novacyt Expects Lower FY EBITDA, Develops Coronavirus Test

Novacyt Signs 3-Year Deal With VGS Group For Distribution Of Molecular Diagnostic Products In France

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novacyt SA

Novacyt SA is a France-based company that develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company develops a secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of over 10 distributors.

Contact Info

13 avenue Morane Saulnier

+33.1.39465104

https://novacyt.com/

Executive Leadership

James Christopher Wakefield

Independent Non-Executive Chairman

Graham D. Mullis

Chief Executive Officer, Executive Director, Member of the Executive Team

Anthony William Dyer

Chief Financial Officer, Executive Director, Company Secretary, Member of the Executive Team

Wendy Karban

Member of the Executive Team, Group Human Resource Manager

Mandy Cowling

Member of the Executive Team, Corporate & Investor Relations Manager

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
5.24
Price To Book (MRQ)
2.48
Price To Cash Flow (TTM)
463.73
Total Debt To Equity (MRQ)
45.91
LT Debt To Equity (MRQ)
20.72
Return on Investment (TTM)
-5.97
Return on Equity (TTM)
-4.29

Latest News

Latest News

Biotech firm Novacyt to launch coronavirus test next week

Biotechnology company Novacyt said on Friday it would launch a certified test for the coronavirus next week, sending its London-listed shares to a record high.

Coronavirus-product testing group Novacyt shares surge again

Shares in biotech company Novacyt , which is launching a coronavirus test, surged on Monday to extend previous big gains made this year on investor hopes it could win regulatory approval for its coronavirus test product.

Biotech company Novacyt seeks emergency approval for coronavirus test

Biotechnology company Novacyt has applied for emergency approval from the U.S. Food & Drug Administration (FDA) as it races to roll out a product that tests for the coronavirus, the company said on Friday.

French biotech Novacyt seeks emergency FDA approval for coronavirus test product

Biotechnology company Novacyt <ALNOV.PA> <NCYT.L> said on Friday it has applied for emergency approval from the U.S. Food & Drug Administration (FDA) for a test product for the coronavirus that has killed almost 640 people.

French biotech Novacyt seeks emergency FDA approval for coronavirus test product

Biotechnology company Novacyt said on Friday it has applied for emergency approval from the U.S. Food & Drug Administration (FDA) for a test product for the coronavirus that has killed almost 640 people.

Healthcare company Novacyt launches new coronavirus test

Healthcare company Novacyt <ALNOV.PA> said on Friday it had launched a new molecular test for the coronavirus currently afflicting China and other parts of the world.

Healthcare company Novacyt launches new coronavirus test

Healthcare company Novacyt said on Friday it had launched a new molecular test for the coronavirus currently afflicting China and other parts of the world.

Healthcare company Novacyt launches new coronavirus test

Healthcare company Novacyt said on Friday that it had launched a new molecular test for coronavirus, which is currently afflicting China and other parts of the world.

BRIEF-Novacyt FY Net Loss Narrows To EUR 5.4 Million

* FY NET LOSS EUR 5.4 MILLION VERSUS EUR 5.7 MILLION YEAR AGO

BRIEF-Novacyt ‍Signs Assay Development Contract For Diagnosis Of Respiratory Infections With GenePOC​

* SIGNS ASSAY DEVELOPMENT CONTRACT FOR DIAGNOSIS OF RESPIRATORY INFECTIONS WITH GENEPOC

BRIEF-Novacyt ‍announces full redemption and settlement of 40 pending Yorkville convertible bonds

* ANNOUNCES FULL REDEMPTION AND SETTLEMENT OF 40 PENDING CONVERTIBLE BONDS ( "OCA") UNDER YORKVILLE FACILITY AGREEMENT, WITH IMMEDIATE EFFECT

BRIEF-Novacyt shares start trading on AIM of London Stock Exchange on Nov 1

* SHARES ADMITTED TO TRADING ON AIM, MARKET OPERATED BY LONDON STOCK EXCHANGE, FROM 8 AM GMT ON NOV 1

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up